Trend 1: Financing private and public biotech deals will continue to focus on investors like the prior year (2021). According to Evaluate Pharma, biotechnology companies had a record-setting $24 billion in venture capital (VC) during the first three quarters of 2021, surpassing the nearly $20 billion raised in all of 2020. (Genetic Engineering and News, January 2022)

Trend 2: Talent and staffing will continue to be challenging since there are not enough trained scientific hands to staff many biotech companies. Recruitment and retention are top of mind for everyone in biotech (Geek wire, January 2022)

Trend 3: Artificial intelligence is emerging to fuel many of biotech's advances which can analyze enormous troves of data with accuracy and speed. And while AI's biotech applications focus on cancer breakthroughs and treatments. For example, AI to target cancers has grabbed the attention of investors.

Trend 4: During the last few years, mental health has made its way to the forefront of public consciousness. Two years of isolation from loved ones' jobs and financial stresses have people openly speaking about their anxiety, depression, trauma, and other mental health issues, which are undeniably a biotechnology health focus for 2022. New advances in technology such as wearables brain imaging and neuro-targeted therapeutics are in high demand during the unspoken health crisis of mental health.